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In conclusion, this study showed high rates of self-reported
improvement in patients’ QoL after a mean interval of
10 years following ETS for palmar hyperhidrosis.
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Pharmacological treatments in pregnant
women with psoriasis in the U.S.A.
DOI: 10.1111/bjd.13306
DEAR EDITOR, Psoriasis commonly occurs in adults of childbear-
ing age.1 Most pregnant women experience improvement
Table 1 Top 10 psoriasis drugs (and pregnancy category X drugs) used by pregnant women (n = 386)
Rank
(based on total)
Top 10 drugs and
category X drugs
FDA
pregnancy
category
Average
prescription
number,
mean  SD Total, n (%)
Trimester 1,
n (%)
Trimester 2,
n (%)
Trimester 3,
n (%) P-value
1 Triamcinolone
acetonide
C 18  15 41 (106) 32 (83) 25 (65) 26 (67) 057
2 Clobetasol C 19  12 36 (93) 33 (85) 21 (54) 20 (52) 010
3 Betamethasone
dipropionate
C 14  08 27 (70) 22 (57) 16 (41) 15 (39) 043
4 Calcipotriene C 24  41 26 (67) 24 (62) 14 (36) 14 (36) 013
5 Fluocinonide C 15  10 13 (34) 11 (28) 6 (16) 6 (16) 033
6 Hydrocortisone C 13  07 10 (26) 9 (23) 9 (23) 8 (21) 096
7 Pimecrolimus C 16  11 8 (21) 8 (21) 6 (16) 5 (13) 069
8 Fluocinolone C 14  05 7 (18) 6 (16) 3 (08) 4 (10) 058
9 Mometasone C 13  05 6 (16) 6 (16) 4 (10) 2 (05) 036
10 Desonide C 14  09 5 (13) 5 (13) 2 (05) 2 (05) 037
– Methotrexate X 15  07 2 (05) 2 (05) 1 (03) 0 037
– Tazarotene X 10  00 2 (05) 2 (05) 1 (03) 1 (03) 078
U.S. Food and Drug Administration (FDA) pregnancy categories: A, large studies suggest no evidence of harm; B, animal studies show
adverse effects and human studies fail to show adverse effects or animal studies fail to show adverse effects and there are no adequate human
studies; C, animal studies show adverse risks, but no adequate human studies; D, evidence of human fetal risk from human studies or mar-
keting or investigational experiences; X, evidence that the drug causes harm to the fetus, the risks clearly outweigh the benefits for pregnant
women.4
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in psoriasis due to immunomodulatory changes from
increased oestrogen, whereas some women’s psoriasis wors-
ens with pregnancy.2 Psoriasis treatment in pregnant women
requires weighing the risks and benefits to both mother
and fetus.3 The U.S. Food and Drug Administration assigns
pregnancy categories A–D and X, profiling a drug’s relative
risk when used during pregnancy (Table 1);4 the potential
benefits of category C and D drugs may outweigh their
potential risks.
Studies have made recommendations for managing psoriasis
treatments in pregnant women based on the literature,4,5
which indicate moisturizers and low-to-midpotency topical
corticosteroids (category C) as first-line treatments, narrow-
band/broadband ultraviolet B as second-line treatments, and
tumour necrosis factor inhibitors (category B), ciclosporin
(category C) and systemic corticosteroids (category C) as
third-line treatments.5 Category X drugs, methotrexate and
tazarotene, are contraindicated in pregnancy. Considering
these recommendations, this study set out to examine what
psoriasis medications physicians are prescribing in practice to
pregnant women.
The Truven 2003–2007 MarketScanTM Medicaid Database,
containing administrative claims for over 30 million Medicaid
enrolees (who were generally patients with lower income)
from multiple geographically dispersed states in the U.S.A.,
was analysed for this retrospective cohort study. Pregnant
patients with psoriasis were identified using inpatient/outpa-
tient service records. Each pregnant woman’s gestational
period was identified by our invented methods, which
approximated pregnancy start and end dates based on our
algorithm adapted from existing protocols along with national
averaged birth outcome-specific gestational periods.6–8
Figure 1 details the inclusion/exclusion algorithm of the study
subjects; the final study sample contains 386 pregnant women
MarketScan Medicaid 2003–
2007 Pregnant women with 
psoriasis (first pregnancy) a
n = 17 247
Pregnant women with clear 
end point
n = 17 102 (99·2%)
Simultaneous multiple 
outcomesb
n = 145 (0·8%)
Pregnant women with entire 
gestational period in dataset c
n = 14 718 (86·1%)
Gestational period extends 
beyond start point c
n = 2384 (13·9%)
Pregnant women with 
psoriasis who previously saw 
physician for psoriasis 
treatment d
n = 560 (3·8%)
Not previously seen for 
psoriasis treatment d
n = 14 158 (96·2%)
Twins
n = 3 (0·8%)
Single
n = 307 (79·1%)
Stillborn
n = 1 (0·3%)
Ectopic
n = 6 (1·6%)
Abortion
n = 69 (17·9%)
Final Study Sample: 
Pregnant women with 
psoriasis who filled psoriasis 
prescription e
n = 386 (68·9%)
Did not fill psoriasis medication 
during pregnancy e
n = 174 (31·1%)
Pregnancy outcomes: f
(Estimated pregnancy length: 
34 weeks; SD: 11·9)
Has ever seen a 
dermatologist
n = 106 (27·5%)
Has ever seen only 
a nondermatologist
n = 280 (72·5%)
Fig 1. Determining study subjects from MarketScan Medicaid 2003–2007. aOnly the first pregnancy of a woman in the study period was
considered because of the reliance on averages to estimate gestational period. Considering multiple outcomes for each person could result in
overlaps in estimated gestational time. Psoriasis diagnosis was determined by outpatient records using the International Classification of Diseases,
ninth revision (ICD-9) code 6961. bThis study excluded patients who had data errors such as an unreasonable age and simultaneous multiple
birth outcomes. cIn order to determine the use of psoriasis medications, only women with psoriasis whose entire estimated gestational period was
between the start and end of the dataset (1 January 2003 and 31 December 2007) were included. dIn order to capture the psoriasis medication
use across patients’ entire gestational periods, the pregnancies before the first diagnosis of psoriasis during the study period were excluded.
ePatients who did not fill psoriasis medications during pregnancy were excluded. fPregnancy outcome categories and ICD-9 codes: single born
(650.xx and V270), twins (65101, 65131 and V272–3), triplets (65111 and 65141), quadruplets (65121 and 65151), stillborn (V271,
V274 and V277), abortions (632.xx, and 634.xx–637.xx), ectopic pregnancies (633.xx). Only categories with nonzero counts are shown.
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with psoriasis who filled psoriasis prescriptions. The mean age
at pregnancy was 237  646 years, and the estimated aver-
age pregnancy length was 34  119 weeks. The majority of
study subjects were White (288, 746%), followed by Black
(65, 168%), other race (26, 67%) and Hispanic (seven,
18%).
Table 1 shows the top 10 most popular prescriptions and
two category X drugs of special interest, which are reported as
the percentage and average number of prescriptions. Psoriasis
medications were further categorized by drug type and
potency level (corticosteroids only) (Table 2). The most com-
monly prescribed medications (based on percentage of pre-
scriptions) were topical corticosteroids (122, 316%),
followed by ‘other’ topical products including topical vitamin
D analogues, pimecrolimus, tacrolimus, topical retinoid, coal
tar and calcipotriene products (41, 106%). Most topical corti-
costeroids were low/midpotency. Four patients received meth-
otrexate or tazarotene during pregnancy; two of them
received the medication for the entire gestational period.
Looking at the trend of drug use over three trimesters, Table 1
shows no significant change across trimesters in the propor-
tion of women receiving the top 10 products. However, there
were significant decreases across trimesters in the use of
topical corticosteroids (relative change 14%; P = 0001),
other topical products (relative change 44%; P = 003) and
class 1 (superpotent) corticosteroids (relative change 38%;
P = 003).
Our study shows that prescribing patterns were mostly in
line with the newer treatment recommendations for pregnant
women with psoriasis.4,5,9 More than two-thirds of women
who had psoriasis before becoming pregnant still received
some form of treatment during their pregnancy. The most
common treatments prescribed to pregnant women with pso-
riasis were topical products; topical corticosteroids combined
were overwhelmingly the most frequently prescribed drugs
and are within the newly recommended standard of care for
treatment of psoriasis in pregnancy.5 The use of topical corti-
costeroids in high-potency or prolonged doses increases risk
of low birthweight; however, in cases where topical emol-
lients have failed, these drugs are still considered a safe first-
line treatment in low-potency or short-term doses.5,10 The
significant decrease across gestational periods in prescriptions
for superpotent corticosteroids, as well as corticosteroids over-
all, is in line with these recommendations, suggesting that
physicians are weighing the risks of these more potent drugs
during pregnancy. However, we cannot rule out that the dis-
ease severity decreased to the point that no high-potency cor-
ticosteroids are required.
Calcipotriene, a first-line treatment for pregnant women
with psoriasis due to its safety and effectiveness, accounted
for only 67% of filled prescriptions; however, it had the
highest average number of fills (mean 24  41). Alarm-
ingly, four pregnant women received prescriptions for meth-
otrexate or tazarotene. Care should be taken to ensure
patients of childbearing potential are counselled on the abor-
tifacient and teratogenic effects of methotrexate and other
category X drugs.9
There are a few limitations in this study. Firstly, it did not
include over-the-counter products. Secondly, we focused only
on the U.S. Medicaid population, which may not be generaliz-
able to patients with other forms of insurance or in other
countries. Thirdly, this study considered only the first preg-
nancy of a woman in order to avoid indeterminacy of possible
overlapped gestational time from the estimation. Despite these
limitations, this paper contributes to the field of psoriasis
pregnancy treatment decisions, which lacks information as to
what treatments have been given to pregnant women with
psoriasis.
Table 2 Use of psoriasis drugs in pregnant women by drug type, and corticosteroids by drug potency
Average prescription
number, mean  SD Total, n (%) Trimester 1, n (%) Trimester 2, n (%) Trimester 3, n (%) P-value
Drug type (n = 386)
Topical corticosteroid 23  21 122 (316) 102 (301)a 68 (256)a 65 (259)a 0001**
Oral corticosteroid – 0 0 0 0 –
Biological 25  07 2 (05) 2 (05) 0 1 (03) 037
Systemic 15  07 2 (05) 2 (05) 1 (03) 0 037
Other 23  33 41 (106) 39 (101) 23 (60) 22 (57) 003*
Corticosteroid potency (n = 122)
1 20  14 42 (344) 39 (320) 24 (197) 24 (197) 003*
2 16  10 21 (172) 18 (148) 11 (90) 10 (82) 020
3 14  07 14 (115) 13 (107) 8 (66) 6 (49) 021
4 17  18 42 (344) 33 (270) 24 (197) 26 (213) 035
5 14  10 23 (189) 17 (139) 12 (98) 14 (115) 061
6 16  08 16 (131) 15 (123) 8 (66) 9 (74) 023
7 16  10 21 (172) 18 (148) 11 (90) 10 (82) 020
aNot all subjects were prescribed topical corticosteroids in all trimesters. Pearson v2-tests were used to examine the trend of drug use over
trimesters. *P < 005; **P < 001.
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Two cases of severe hidradenitis suppurativa
with failure of anakinra therapy
DOI: 10.1111/bjd.13292
DEAR EDITOR, Hidradenitis suppurativa (HS) is a chronic inflam-
matory and debilitating skin disease with a poor response to
traditional treatments.
Of the new therapeutic options available, successful off-
label use of anakinra has been reported in patients with severe
HS, and in a patient with pyoderma gangrenosum, acne and
suppurative hidradenitis (PASH) syndrome.1–4
We describe our experience with two patients with severe
HS, both of whom were treated with subcutaneous adminis-
tration of anakinra 100 mg daily.
Physical examination and laboratory analyses were under-
taken on both patients every 4 weeks. The main aim was to
evaluate their response after 12 weeks of treatment.
The patients completed the Dermatology Life Quality Index
(DLQI)5 questionnaire and underwent Physician’s Global
Assessment (PGA), which gives a score ranging from 0 (clear)
to 5 (very severe), at both the beginning and the end of the
treatment. Owing to the extent and severity of the lesions, the
Hidradenitis Suppurativa Score, simplified by Sartorius et al.,6
was considered inadequate to evaluate the treatment response.
The first patient was a 32-year-old man with PASH syn-
drome of 15 years, with no response to multiple antibiotics,
methotrexate, sulfone, ciclosporin, finasteride, surgery and
biological therapies (infliximab, adalimumab, ustekinumab).
He was an ex-smoker with a body mass index (BMI) of 25
and a family history of HS. At the start of treatment, the
patient had a DLQI score of 17 and a PGA score of 4.
In the past year he had been treated with oral corticoster-
oids (40 mg daily), trimethoprim/sulfamethoxazole (800/
160 mg daily) and amoxicillin/clavulanic acid (2 g three
times daily). Considering the limited control of his lesions he
was also treated with anakinra. Analysis of the cytokine profile
in a blood sample did not show high levels of interleukin-1b
(3 pg mL1; normal range 0–5 pg mL1). After 12 weeks
there were no changes in DLQI or PGA scores and therefore
treatment with anakinra was stopped (Fig. 1a–d).
The second patient was a 30-year-old man with acne, Crohn
disease and severe HS of 5 years, localized mainly in the groin
area, with resistance to systemic drugs (multiple antibiotics,
isotretinoin, infliximab) and partial results with surgery. The
patient had a DLQI score of 15 and PGA score of 4. He was a
nonsmoker with a BMI of 19.9 and no family history of HS.
The patient was being treated with isotretinoin (30 mg
daily), clindamycin (300 mg twice daily) and levofloxacin
(500 mg twice daily) when he started receiving anakinra. After
2 months both facial and inguinal abscesses worsened (Fig. 2a,
b), with a resulting PGA score of 5 and a DLQI score of 17.
Treatment with anakinra was stopped. Significant improvement
was seen after a 10-day course of oral corticosteroids.
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